Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW9H4A)

• Drug Name: SCH 50911 Drug Info
• Synonyms: SCH 50911; 160415-07-6; UNII-13OB0KEU61; 733717-87-8; 13OB0KEU61; SCH50911; (2S)-(+)-5,5-Dimethyl-2-morpholineacetic acid; SCH-50911; NCGC00024915-02; [(2s)-5,5-Dimethylmorpholin-2-Yl]acetic Acid; DSSTox_RID_81045; DSSTox_CID_25670; DSSTox_GSID_45670; 2-[(2S)-5,5-dimethylmorpholin-2-yl]acetic acid; SCH-50911 free base; CAS-160415-07-6; Spectrum_001764; SCH 50911 free base; AC1NSKM9; Biomol-NT_000243; 2-Morpholineacetic acid, 5,5-dimethyl-, (2S)-; KBioSS_002245; SCHEMBL340881; BPBio1_000749; GTPL1075; ZINC6164; CHEMBL1895916

Indication

Disease Entry	ICD 11	Status	REF
Absence seizure	8A68.2	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 5311429
  CAS Number: CAS 733717-87-8
  TTD Drug ID: DMW9H4A

Molecule-Related Drug Atlas

Drug(s) Targeting Gamma-aminobutyric acid B receptor (GABBR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[3]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[4]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[5]
Progabide	DM671NG	Depression	6A70-6A7Z	Approved	[6]
Arbaclofen placarbil	DMO628K	Fragile X syndrome	LD55	Phase 3	[7]
[3H](R)-(-)-baclofen	DMLRHM5	Multiple sclerosis	8A40	Phase 3	[8]
Arabaclofen	DMZB9RI	Fragile X syndrome	LD55	Phase 3	[9]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[10]
SGS742	DM5XYFH	Schizophrenia	6A20	Phase 2	[11]
SSTarbaclofen	DMRGTZ2	Autism spectrum disorder	6A02	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gamma-aminobutyric acid B receptor (GABBR)	TTDCVZW	GABR1_HUMAN; GABR2_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1075).
• [2] Activation of nigral dopamine neurons by the selective GABA(B)-receptor antagonist SCH 50911. J Neural Transm. 1999;106(5-6):383-94.
• [3] Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
• [6] Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47.
• [7] Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
• [9] Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84.
• [10] 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
• [11] SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.
• [12] Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128.